Wall Street brokerages expect Aptevo Therapeutics Inc (NASDAQ:APVO) to announce ($0.59) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Aptevo Therapeutics’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.58). Aptevo Therapeutics posted earnings per share of $0.14 during the same quarter last year, which would suggest a negative year over year growth rate of 521.4%. The firm is expected to report its next quarterly earnings report on Thursday, November 8th.

On average, analysts expect that Aptevo Therapeutics will report full-year earnings of ($2.42) per share for the current fiscal year, with EPS estimates ranging from ($2.47) to ($2.36). For the next year, analysts expect that the company will post earnings of ($2.35) per share, with EPS estimates ranging from ($2.68) to ($2.02). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVO) last issued its earnings results on Thursday, August 9th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. The company had revenue of $6.83 million during the quarter, compared to analyst estimates of $4.17 million. Aptevo Therapeutics had a net margin of 74.01% and a negative return on equity of 45.53%.

A number of brokerages have issued reports on APVO. ValuEngine lowered shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, June 29th. Zacks Investment Research raised shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Aptevo Therapeutics in a research note on Friday, August 10th.

Hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC lifted its stake in shares of Aptevo Therapeutics by 215.4% in the 1st quarter. Citadel Advisors LLC now owns 39,653 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 27,079 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Aptevo Therapeutics in the 2nd quarter valued at $148,000. Northern Trust Corp lifted its stake in shares of Aptevo Therapeutics by 21.2% in the 2nd quarter. Northern Trust Corp now owns 70,416 shares of the biotechnology company’s stock valued at $352,000 after purchasing an additional 12,299 shares during the last quarter. Spark Investment Management LLC lifted its stake in shares of Aptevo Therapeutics by 82.8% in the 1st quarter. Spark Investment Management LLC now owns 129,400 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 58,600 shares during the last quarter. Finally, EAM Investors LLC acquired a new stake in shares of Aptevo Therapeutics in the 2nd quarter valued at $552,000. 33.08% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:APVO traded down $0.04 during trading on Wednesday, reaching $5.05. 28,254 shares of the company traded hands, compared to its average volume of 75,604. The firm has a market capitalization of $114.25 million, a P/E ratio of -3.30 and a beta of 0.68. Aptevo Therapeutics has a 1-year low of $2.05 and a 1-year high of $6.35. The company has a quick ratio of 3.50, a current ratio of 3.66 and a debt-to-equity ratio of 0.27.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Further Reading: Are Wall Street analysts’ stock ratings worth following?

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.